QLT Announces Reduction in Force

QLT Announces Reduction in Force

VANCOUVER, British Columbia, Dec. 6, 2012 (GLOBE NEWSWIRE) -- QLT Inc.
(Nasdaq:QLTI) (TSX:QLT) today announced a 42% reduction of its workforce to
better align its resources with the Company's corporate objectives following
the recent sale of Visudyne^® to Valeant Pharmaceuticals International, Inc.
("Valeant"). QLT expects to record a restructuring charge of approximately
$2.0 million relating to this reduction in force. The Company also expects the
reorganization to result in approximately $3.8 million in reduced annualized
expenses once the reduction is fully implemented in the first half of 2013.

"QLT's Board of Directors wishes to sincerely thank all of our departing
employees for their dedicated and loyal service to the company. Each of their
contributions has been instrumental to our consolidation of development
activities and transition of Visudyne to Valeant," said Jason M. Aryeh,
Chairman of QLT."QLT's remaining 38 employees are focused on the clinical
development of our very promising Synthetic Oral Retinoid program, while the
Board continues to acutely focus on delivering value to shareholders."

The affected employees will leave the Company during the first half of 2013,
the majority of which will coincide with the completion of various transition
services provided to Valeant under the Transition Services Agreement entered
into in September 2012 between QLT and Valeant in connection with the sale of
QLT's Visudyne business to Valeant.

About QLT

QLT is a biotechnology company dedicated to the development and
commercialization of innovative ocular products that address the unmet medical
needs of patients and clinicians worldwide. We are focused on developing our
synthetic retinoid program for the treatment of certain inherited retinal

QLT's head office is based in Vancouver, Canada and the Company is publicly
traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT).
For more information about the Company's products and developments, please
visit our web site at www.qltinc.com.

Visudyne^® is a registered trademark of Novartis AG

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI"
and on The Toronto Stock Exchange under the trading symbol "QLT."

The QLT Inc. logo is available at

Certain statements in this press release constitute "forward-looking
statements" of QLT within the meaning of the Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. Forward-looking statements
include, but are not limited to: statements concerning the expected
restructuring charge and reduced annualized expenses from the reduction in
QLT's workforce; statements concerning the potential of our Synthetic Oral
Retinoid Program; and statements which contain language such as: "assuming,"
"prospects," "goal," "future," "projects," "potential," "believes," "expects";
"hopes" and "outlook." Forward-looking statements are predictions only which
involve known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from those expressed in such
statements. Many such risks, uncertainties and other factors are taken into
account as part of our assumptions underlying these forward-looking statements
and include, among others, the following: risks and uncertainties related to
the impacts that QLT's strategic initiatives will have on the market price of
our securities; risks and uncertainties relating to QLT's ability to implement
the workforce reduction successfully and achieve anticipated savings; risks
and uncertainties as to the impact of the workforce reduction on the
development of QLT's programs or our other strategic initiatives;
uncertainties relating to our development plans, timing and results of the
clinical development and commercialization of our products and technologies;
assumptions related to continued enrollment trends, efforts and success, and
the associated costs of these programs; outcomes for our clinical trials
(including our Synthetic Oral Retinoid program) may not be favorable or may be
less favorable than interim/preliminary results and/or previous trials; there
may be varying interpretations of data produced by one or more of our clinical
trials; the timing, expense and uncertainty associated with the regulatory
approval process for products to advance through development stages; risks and
uncertainties associated with the safety and effectiveness of our technology;
risks and uncertainties related to the scope, validity, and enforceability of
our intellectual property rights and the impact of patents and other
intellectual property of third parties; the Company's future operating results
are uncertain and likely to fluctuate; currency fluctuations; and general
economic conditions and other factors described in detail in QLT's Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the
U.S. Securities and Exchange Commission and Canadian securities regulatory
authorities.Forward-looking statements are based on the current expectations
of QLT and QLT does not assume any obligation to update such information to
reflect later events or developments except as required by law.

CONTACT: QLT Inc. Contacts:
         Investor & Media Relations
         Andrea Rabney or David Pitts
         Argot Partners

company logo
Press spacebar to pause and continue. Press esc to stop.